Nkarta Reports $40.4 Million Net Loss in Q2 2026, Driven by Increased Operating Expenses

Nkarta, Inc. reported significant financial results for the second quarter of 2026, revealing a net loss of $40.4 million, compared to a net loss of $23.0 million in the same period last year. For the six months ending June 30, 2026, the company recorded a net loss of $68.2 million, up from $55.0 million in the prior year. The increase in losses is attributed to higher operating expenses, which totaled $43.1 million for the quarter, a 58.7% increase from $27.2 million in Q2 2025. The rise in expenses was primarily driven by increased research and development costs associated with the clinical trials for its lead product candidate, NKX019, targeting autoimmune diseases.

In terms of operational metrics, Nkarta's research and development expenses rose to $29.0 million for the second quarter of 2026, up from $20.8 million in the same quarter of 2025. This increase reflects a $6.1 million rise in program costs, largely due to higher clinical spending and manufacturing expenses related to NKX019. General and administrative expenses also surged to $14.1 million, compared to $6.4 million in the prior year, largely due to an $8.0 million impairment charge related to equipment and leasehold improvements. The company’s accumulated deficit reached $716.5 million as of June 30, 2026.

Nkarta's financial position showed a decline in total assets, which decreased to $337.6 million from $404.2 million at the end of 2025. The company’s cash and cash equivalents fell to $24.9 million, down from $39.6 million at the end of the previous fiscal year. The decrease in cash reserves is attributed to ongoing operational losses and increased spending on clinical trials. The company reported total liabilities of $89.9 million, slightly down from $91.9 million at the end of 2025.

Strategically, Nkarta is focused on advancing its NK-cell therapy platform, with ongoing clinical trials for NKX019. The company has made significant progress in its Ntrust-1 and Ntrust-2 trials, which are evaluating NKX019 for various autoimmune conditions. Recent protocol amendments approved by the FDA aim to streamline patient administration and monitoring processes, potentially enhancing patient access to the therapy. However, Nkarta continues to face challenges, including the need for substantial additional capital to fund its operations and clinical development efforts.

Looking ahead, Nkarta anticipates that its operating expenses will continue to rise as it progresses through clinical trials and seeks regulatory approvals for its product candidates. The company plans to raise additional capital through equity or debt financing, as it has done in the past, to support its long-term development strategy. Nkarta's management believes that its current cash reserves will be sufficient to meet its operational needs for at least the next twelve months, but acknowledges the inherent risks and uncertainties associated with its clinical development and funding requirements.